Why Oragenics Inc’s (OGEN) Stock Is Up 5363.77%
As of Monday, January 23, Oragenics Inc’s OGEN share price has surged by 5363.77%, which has investors questioning if this is right time to sell.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jack Gilleland
Learn more about Oragenics Inc’s (OGEN) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
| Share Statistics | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $0.7 | $203.5 | 1% |
|
| Shares Out (Mil) | 4.5 | 55.2 | 13% |
|
| Institutional Ownership | 95.7% | 93.3% | 68% |
|
| Float (Mil) | 4.4 | 40.4 | 11% |
|
| Beta | 1.27 | 1.05 | 73% |
|
| Avg Daily Volume (000s) | 5,291 | 569 | 92% |
|
| Price Change (52-week) |
(84.3%) | 38.8% | 8% |
|
| Growth | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 18.0% | (10.7%) | 70% |
|
| EPS (5yr) | 64.8% | 15.4% | 97 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.8% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($44) | 29% |
|
| EPS (TTM) | ($2.195) | ($1.400) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($35) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $-0 | $142 | 4% |
|
| Valuation | OGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.65 | 1.96 | 17% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (120.3%) | (47.0%) | 4% |
|
| ROE | (176.1%) | (51.8%) | 5% |
|
| Liabilities to Assets | 66.7% | 29.6% | 62% |
|
| F-Score | 2 | 3 | 7% |
|
Oragenics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors